We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on new technology integration in the field of bioanalysis.
Find out more about the evolution of fit-for-purpose biomarker validations from an LBA perspective in this free article from Bioanalysis.
2017 White Paper on recent issues in bioanalysis: aren’t BMV guidance/guidelines ‘Scientific’? (Part 1 – LCMS: small molecules, peptides and small molecule biomarkers)
This White Paper is from the 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) that took place in Los Angeles/Universal City, California from 3 April 2017 to 7 April 2017. The conference included a full week of bioanalysis, biomarkers and immunogenicity.
Issue 23 of Bioanalysis volume 9 is now available, including an editorial discussing the matrix effects, a methodology on assay signaling and a White Paper on the rise of hybrid LBA/LCMS immunogenicity assays.
This article describes three case studies of a plug-and-play immuno polymerase chain reaction (iPCR) technique used to measure biomolecules. Learn more in this article from Bioanalysis.
Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons
This review compares and discusses all available approaches that can be used to assess key assay parameters for pharmacokinetic and biomarker ligand-binding assays. Find out more in this article from Bioanalysis.
3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis
In this review article the authors outline the increase in sensitivity and dynamic range when using fluorogenic 3-(4-hydroxyphenyl)propionic acid in preference of other conventional colorimetric ELISA, LBA technologies and LC-MS assays.
LC–MS/MS strategies for therapeutic antibodies and investigation into the quantitative impact of antidrug-antibodies
In this original research article, the authors present two novel, high-throughput LC–MS/MS strategies for quantification of monoclonal antibodies in human serum and examine the potential impact of antidrug antibodies.
Validation of a ligand-binding assay for active protein drug quantification following the ‘free analyte QC concept’
In this research article the authors describe the validation of a ligand-binding assay for active protein drug quantification and address practical challenges as well as regulatory implications.
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity)
In part 3 of this White Paper from this years 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) which took place in Orlando, the authors discuss recommendations for large molecule bioanalysis using LBA, biomarkers and immunogenicity.